630 related articles for article (PubMed ID: 32979839)
1. EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins.
Remon J; Hendriks LEL; Cardona AF; Besse B
Cancer Treat Rev; 2020 Nov; 90():102105. PubMed ID: 32979839
[TBL] [Abstract][Full Text] [Related]
2. Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions.
Floc'h N; Martin MJ; Riess JW; Orme JP; Staniszewska AD; Ménard L; Cuomo ME; O'Neill DJ; Ward RA; Finlay MRV; McKerrecher D; Cheng M; Vang DP; Burich RA; Keck JG; Gandara DR; Mack PC; Cross DAE
Mol Cancer Ther; 2018 May; 17(5):885-896. PubMed ID: 29483211
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.
Russo A; Franchina T; Ricciardi G; Battaglia A; Picciotto M; Adamo V
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30901844
[TBL] [Abstract][Full Text] [Related]
4. EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies.
Bai Q; Wang J; Zhou X
Cancer Treat Rev; 2023 Nov; 120():102605. PubMed ID: 37703723
[TBL] [Abstract][Full Text] [Related]
5. Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations.
Hu M; Zhong C; Wang J; Chen J; Zhou T
Front Immunol; 2024; 15():1399975. PubMed ID: 38774882
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the Clinical Characteristics and Prognosis of Advanced Non-Small Cell Lung Cancer with Exon 20 Insertions.
Wang H; Xu Y; Lin J; Huang Y
Cancer Control; 2024; 31():10732748241262190. PubMed ID: 38857163
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations.
Imai H; Minemura H; Sugiyama T; Yamada Y; Kaira K; Kanazawa K; Kasai T; Kaburagi T; Minato K;
Cancer Chemother Pharmacol; 2018 Jul; 82(1):119-127. PubMed ID: 29737372
[TBL] [Abstract][Full Text] [Related]
8. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
9. Role of Anti-EGFR Targeted Therapies in Stage III Locally Advanced Non-small Cell Lung Cancer: Give or Not to Give?
Desai S; Kim C; Veytsman I
Curr Oncol Rep; 2019 Aug; 21(9):84. PubMed ID: 31410582
[TBL] [Abstract][Full Text] [Related]
10. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study.
Yang G; Li J; Xu H; Yang Y; Yang L; Xu F; Xia B; Zhu VW; Nagasaka M; Yang Y; Li Y; Qiu W; Ying J; Ou SI; Wang Y
Lung Cancer; 2020 Jul; 145():186-194. PubMed ID: 32336530
[TBL] [Abstract][Full Text] [Related]
11. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
[TBL] [Abstract][Full Text] [Related]
12. A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer.
Yasuda H; Ichihara E; Sakakibara-Konishi J; Zenke Y; Takeuchi S; Morise M; Hotta K; Sato M; Matsumoto S; Tanimoto A; Matsuzawa R; Kiura K; Takashima Y; Yano S; Koyama J; Fukushima T; Hamamoto J; Terai H; Ikemura S; Takemura R; Goto K; Soejima K
Lung Cancer; 2021 Dec; 162():140-146. PubMed ID: 34808485
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation.
Chantharasamee J; Poungvarin N; Danchaivijitr P; Techawatanawanna S
BMC Cancer; 2019 Jul; 19(1):701. PubMed ID: 31315599
[TBL] [Abstract][Full Text] [Related]
14. Post-progression survival is highly linked to overall survival in patients with non-small-cell lung cancer harboring sensitive EGFR mutations treated with first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
Imai H; Kaira K; Mori K; Kotake M; Mitani M; Kawashima N; Hisada T; Minato K
Thorac Cancer; 2019 Dec; 10(12):2200-2208. PubMed ID: 31595714
[TBL] [Abstract][Full Text] [Related]
15. First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain αC-helix: Two case reports and a literature review.
Han H; Zhang X; Liu X; Zhao J; Zhang J; Zhang J; Zhu H; Jiao S; Tang H
Medicine (Baltimore); 2023 Dec; 102(52):e36667. PubMed ID: 38206746
[TBL] [Abstract][Full Text] [Related]
16. Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of
Yun J; Lee SH; Kim SY; Jeong SY; Kim JH; Pyo KH; Park CW; Heo SG; Yun MR; Lim S; Lim SM; Hong MH; Kim HR; Thayu M; Curtin JC; Knoblauch RE; Lorenzi MV; Roshak A; Cho BC
Cancer Discov; 2020 Aug; 10(8):1194-1209. PubMed ID: 32414908
[No Abstract] [Full Text] [Related]
17. A meta-analysis of the comparing of the first-generation and next-generation TKIs in the treatment of NSCLC.
Li YX; Yang JY; Xu YF; Zhang M; Zhang XP; Chen WY; Lv XD
Math Biosci Eng; 2019 Jun; 16(5):5687-5696. PubMed ID: 31499732
[No Abstract] [Full Text] [Related]
18. The role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced non small cell lung cancer patients harboring EGFR mutation.
Sgambato A; Casaluce F; Maione P; Rossi A; Rossi E; Napolitano A; Palazzolo G; Bareschino MA; Schettino C; Sacco PC; Ciadiello F; Gridelli C
Curr Med Chem; 2012; 19(20):3337-52. PubMed ID: 22664249
[TBL] [Abstract][Full Text] [Related]
19. [Advances in Treatment of Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations].
Yang X; Zhao J
Zhongguo Fei Ai Za Zhi; 2022 May; 25(5):337-350. PubMed ID: 35599009
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations.
Wu JY; Yu CJ; Shih JY
Clin Lung Cancer; 2019 Nov; 20(6):e620-e630. PubMed ID: 31327643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
